Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

Antengene announced that ATG-101, the company’s novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation by the U.S. FDA for the treatment of pancreatic cancer.